Home / News / Events / Events detail
BIONNOVA Beijing Forum 2023 was successfully held at Beijing Palace Garden Hotel & Resorts on 24th November, this forum brought together over 2,000 decision-makers in innovation collaboration, featuring more than 120 pioneers delivering forefront innovation talks, and uniting more than 80 technology-leading enterprises. The forum focused on the latest trends in research and development, production processes, clinical trials, and commercialization for small molecules, antibodies, and cell and gene therapy.
Dr. Jianhua Cai
Senior Vice President of Viva Biotech
Biophysical Platform empowered the development of new drug discovery
Dr. Jianhua Cai, Senior Vice President of Viva Biotech, was an invited speaker and delivered a speech on the topic of "The Application of Biophysics in Innovative Drug Discovery and Development". Since the invention of X-ray crystallography in the early 20th century and its application in the life science field, biophysical techniques have rapidly developed, with methods including X-ray, NMR, MS, and Cyro-EM technology platforms winning numerous Nobel Prizes in Chemistry or Physiology/Medicine. Meanwhile, these biophysical techniques have found wide applications in the field of innovative drug discovery. Dr. Cai, starting from this point, comprehensively introduced the application of Viva Biotech's biophysical technology platform in the study of drug mechanism of action (MOA) and drug screening. Viva Biotech utilizes a series of biophysical techniques such as X-ray, Cryo-EM, HDX-MS, SPR, Intact-MS, and Native-MS for research into the protein tertiary structure, binding affinity, binding sites, binding kinetics, as well as for screening and identification in covalent and non-covalent binding.
In the aspect of drug screening, he noted that Viva has established a comprehensive drug screening platform. This platform is based on its own compound library, which includes a structurally diverse compound library of 200,000 compounds, a fragment compound library of 2,050 compounds, a fragment compound library of 960 compounds, a focused GPCR library of 6,500 compounds, a covalent compound library of 1,000 compounds, and client-provided compound libraries. Technologies like ASMS, SPR, Crystal soaking, and Intact-MS are used to develop affinity screening methods for specific targets, and he discussed specific case applications, particularly Viva's newly developed covalent compound screening method at the cellular level. He also emphasized that Viva's compound library is continuously updated and iterated. Additionally, to meet the market demand for screening traditionally challenging small molecule targets, Viva recently introduced a peptide library based on phage display technology. This includes two types: one is a commercially available linear peptide library of 7aa and 12aa, and a 7aa cyclic peptide library, with diversity reaching 109, and the other is a customizable peptide screening library, which can be internally constructed in 6-8 weeks with diversity higher than 109. The screening cycle for each library is approximately 4 weeks.
Dr. Cai illustrated various biophysical technologies, such as SEC-ASMS and SPR, and explored their roles in the discovery of molecular glues. Additionally, he showcased the practical application of Viva's biophysical technology in innovative drug discovery, highlighting the discovery of the first new mechanistic variant anticancer drug and a novel small molecule PCSK9 variant inhibitor. These successful cases effectively demonstrate Viva's robust capabilities in providing comprehensive one-stop services for new drug discovery.
DuriDuring the exhibition, Viva Biotech hosted a booth to showcase its expertise in new drug discovery, development, and production. The team presented its core technological platforms, including PROTAC/molecular glue technology, protein production and preparation, structural research, cryo-electron microscopy, drug screening, bio-analytical method development platform, chemistry service, computer-aided drug design, and antibody/macromolecule drug development. The core technology platform was highly praised and recognized by the guests. The North China exhibition tour concluded successfully, marking a significant milestone for us. We established numerous industry connections and engaged in meaningful discussions about changes, collaborations, and prospects in the pharmaceutical field. Looking forward, we are excited to meet more like-minded professionals to explore new opportunities in drug development and manufacturing.
Copyright © Viva Biotech All Rights Reserved. 沪ICP备19036061号
- About Us
-
CRO Services
BackCRO ServicesDiscovery Biology Services
- CDMO Services
- EFS Business
- News
- Careers
- Investor Relations
- Contact Us